Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

Contraception Clinical Trial

Official title:

A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03537768
• Other study ID #: CCN013C
• Status: Recruiting
• Phase: Phase 4
• Start date: July 12, 2018
• Est. completion date: September 30, 2020

Study information

• Verified date: October 2019
• Source: Health Decisions
• Contact: Amber Blackmon
• Phone: 919-967-1111
• Email: sblackmon[@]healthdec.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80 kg who present within 72 hours of unprotected intercourse.

Description:

Orally-dosed emergency contraception (EC) is highly effective when used properly. EC is up to 90% effective at preventing pregnancy following unprotected intercourse. Both ulipristal acetate (UPA) and levonorgestrel (LNG) delay or inhibit ovulation when used for EC. For individual women, use of EC provides a critical backup to prevent unintended pregnancy.

However, obesity may severely impair EC effectiveness. Data from two large randomized control trials to identify risk factors for EC failure. A woman of obese body mass index (BMI) (≥30mg/kg2) using LNG-based EC had more than a 4 times greater risk of pregnancy compared to her normal BMI counterpart and a woman of overweight BMI (25-29.9) was at twice the risk of pregnancy. Failure was also associated with a high body weight. LNG-based EC appears to have a ceiling of efficacy at 70 kg and no efficacy for women 80 kg and above. It is believed that by doubling the dose to LNG 3.0 mg, serum levels of LNG are corrected to a therapeutic range.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: September 30, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Be in good general overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care.

2. Between 18 and 40 years inclusive at the enrollment visit.

3. Weight = 80 kg.

4. Have regular menstrual cycles that typically occur every 21-35 days when not using hormonal contraception.

5. If subject is postpartum or post-abortal, she must have experienced a menstrual bleed since the pregnancy ended

6. If a subject recently used non-injectable hormonal contraception, one bleeding episode consistent with menses must have occurred since last use;

7. Willing to avoid use of any hormonal or intrauterine contraception until the end of the study;

8. For women with a recent history of Depo Provera use, the most recent injection must have been at least 6 months before study entry, and the subject must have had at least one normal menstrual cycle (2 consecutive menses);

9. Request emergency contraception within 72 hours (3 days) after unprotected coitus, as defined by lack of contraceptive use, condom breakage (including condoms lubricated with spermicide), or other barrier contraceptive method failure;

10. Have a negative urine pregnancy test at time of screening

11. Reports all acts of unprotected coitus since her prior menses are within 72 hours prior to enrollment;

12. Willing to abstain from further acts of unprotected intercourse until the end of the study;

13. Give voluntary, written informed consent, and agree to observe all study requirements including being available for follow up for at least the next 4 weeks;

14. Accepts that the risk of pregnancy with oral EC is greater than that following placement of a copper IUD for EC.

Exclusion Criteria:

1. Be currently pregnant (positive high-sensitivity urine pregnancy test);

2. Be currently breastfeeding or within 30 days of discontinuing breastfeeding, unless the subject has already had a menses following discontinuation of breastfeeding;

3. Desire to use hormonal systemic contraception within 5 days of study drug use

4. Have had a female sterilization procedure;

5. Have a partner with a history of vasectomy;

6. Current inability to tolerate oral medication;

7. Have impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid replacement therapy in the last year.

8. Have known liver disease;

9. Have known liver abnormalities with elevated enzymes at least twice the upper limit of normal requiring use of liver enzyme inducers.

10. Have known hypersensitivity to the active substance UPA or LNG, or any of the excipients of the study treatment.

11. Have a current need for exogenous hormones.

12. Have concomitant use of strong CYP3A4 inhibitors (as identified by the FDA) or inducers at the time of or planned use within 3 days of dosing;

13. Use any medications that can interfere with the metabolism of hormonal contraceptives; take antibiotics that can interfere with metabolism of hormonal contraceptives at the time of or planned use within 3 days of dosing of the study drug; or use any drugs designated by the FDA as falling in the Pregnancy and Lactation narrative subsections (formerly Category D or X medications).

14. Current or recent (within one month) participation in any other trial of an investigational medicine or device or planning to participate in another clinical trial during this study.

15. Have a history of a bariatric surgery procedure associated with malabsorption.

16. Live outside of the catchment area of the study site.

17. Have used UPA or LNG EC within 30 days prior to enrollment and not had a menses since using the drug.

18. Be a site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities. -

Related Conditions & MeSH terms

• Contraception
• Emergencies

Intervention

Drug:
• Ulipristal Acetate
UPA Tablet
• Levonorgestrel
LNG Tablet
• Levonorgestrel
LNG Tablet (x2)

Locations

Country	Name	City	State
United States	Johns Hopkins Bayview Medical Center	Baltimore	Maryland
United States	Planned Parenthood League of Massachusetts	Boston	Massachusetts
United States	University of Chicago	Chicago	Illinois
United States	University of Cincinnati-Holmes Hospital	Cincinnati	Ohio
United States	University Hospitals of Cleveland MacDonald Women's Hospital	Cleveland	Ohio
United States	University of Colorado	Denver	Colorado
United States	University of Hawaii	Honolulu	Hawaii
United States	Essential Access Health	Los Angeles	California
United States	Bellevue Hospital Center	New York	New York
United States	Columbia University	New York	New York
United States	Eastern Virginia Medical School	Norfolk	Virginia
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Pittsburgh/Magee Women's Hospital	Pittsburgh	Pennsylvania
United States	Oregon Health Science University	Portland	Oregon
United States	Women & Infants Hospital of Rhode Island	Providence	Rhode Island
United States	University of California, Davis	Sacramento	California
United States	University of Utah	Salt Lake City	Utah
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Health Decisions	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of pregnancies of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg in women with weight = 80 kg for emergency contraception (within 72 hours of unprotected intercourse).		1-3 months
Secondary	Incidence of treatment emergent adverse events of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg in women with weight =80 kg seeking emergency contraception.		1-3 months